On this page
What it is
A synthetic peptide sequence described as being derived from a protein found in gastric juice. The 'body protection compound' name comes from the original research group, not from a demonstrated protective effect in humans.
How it is proposed to work
Animal work has proposed effects on angiogenesis, growth-factor signalling and nitric oxide pathways. These mechanisms are hypotheses drawn from animal models; none is confirmed in humans.
Approved medical uses
None. BPC-157 has no approved human medical indication in the jurisdictions we track. Any use is outside an approved label.
Human research
Each entry states what the study found and, separately, what it cannot show.
No adequate published human research. This absence is the reason for the evidence grade above — it is not a gap we can fill with animal data.
Preclinical research
Animal and laboratory work. Useful for generating hypotheses; it cannot establish that something works in people.
- Narrative review2019
Critical review of BPC 157 in tendon, ligament and skeletal muscle healing
Finding. A critical review of the BPC 157 soft-tissue literature, focused on tendon, ligament and skeletal muscle healing. Its authors report that all studies investigating BPC 157 have demonstrated consistently positive and prompt healing effects for various injury types, both traumatic and systemic, and that skeletal muscle injury models have suggested a beneficial effect not only for disturbances resulting from direct trauma but also for systemic insults. The same authors state that the majority of studies have been performed on small rodent models and that the efficacy of BPC 157 is yet to be confirmed in humans.
Limitation. This is a review, not an experiment: the abstract sets out no search strategy, inclusion criteria or synthesis method, so the uniformly positive picture it reports cannot be checked for selection, and the abstract reports no model, comparison or effect size of its own. The literature it reviews is, by its authors' own account, majority small-rodent, with the efficacy of BPC 157 yet to be confirmed in humans; they further note that over the past two decades only a handful of research groups have performed in-depth studies of the peptide, so the positive picture rests on a narrow and concentrated body of work. On safety they report both that there are few studies reporting any adverse reactions to administration and that the precise healing mechanisms still need to be understood before clinical realisation — an absence of reported harm in a literature this narrow is not a human safety dataset.
- Animal1996
Induced gastric lesion models in rats
Finding. In rats, BPC 157 given intraperitoneally (10 micrograms/kg and 10 ng/kg) protected the gastric mucosa against lesions produced by ethanol, by restraint stress and by indomethacin. Protection was still evident in rats whose sensory nerve fibres had been destroyed by neurotoxic capsaicin, given either in adulthood or as newborns, in all of these assays, although the negative influence of capsaicin on the lesions consistently affected BPC 157's salutary activity. After neonatal capsaicin, protection was abolished when the nanogram regimen (10 ng/kg) was applied once, but was fully reversed when the same dose was given daily. A low, excitatory dose of capsaicin appeared to increase the protective effect.
Limitation. Rat gastric-lesion models only, with injury induced chemically, pharmacologically and by restraint, and outcomes read as mucosal lesions rather than any clinical endpoint. The abstract states no total number of animals. The work comes from the Zagreb group that produced most of the original research on this peptide, so it is not independent replication. This is not human evidence, and no adequate human replication exists.
Potential safety concerns
- SeriousInsufficient
There is no adequate human safety dataset. Absence of reported harm is not evidence of safety — it reflects the absence of systematic human study.
- SeriousPromising
Consumer-directed products vary widely in identity and purity. Independent testing has repeatedly found mislabelled peptide products.
Known interactions and contraindication considerations
- Not characterised in humans.
This list is not exhaustive and is not a substitute for a clinician reviewing your full medication history.
Regulatory status
Status is shown per jurisdiction and is accurate only as of the date stated. Where a compound is approved, the approval is bound to a specific formulation, manufacturer and indication — shown in the detail column.
| Jurisdiction | Standing | Detail |
|---|---|---|
United States FDA | Not approved as of 24 Jul 2026 | Not an approved drug. It has been the subject of FDA compounding-category consideration. A committee discussion or nomination is not an approval and must not be presented as one. |
European Union EMA | Unapproved / investigational as of 1 Jun 2026 | No marketing authorisation. |
India CDSCO | Unapproved / investigational as of 1 Jun 2026 | Would fall under the new-drug pathway. No approval for sale or distribution for human use. |
How it is being used
What the grey community actually runs, the reasoning they give, and our read on whether it follows from known biology. This is observation, not evidence, and not a recommendation.
Tendon, ligament and muscle injury
What is run
Daily injection over multi-week blocks, sometimes near the injury site on the reasoning that local delivery helps, alongside continued training.
Their mechanistic reasoning
That effects on angiogenesis, growth-factor signalling and nitric oxide pathways accelerate the repair process, based on consistent findings across rodent tendon and muscle injury models.
Reported in the community’s own terms. Not our position.
Stacked with
- TB-500—Different proposed repair pathways, expected to be complementary.
- Progressive loading rehabilitation—The only component here with human outcome evidence behind it.
Regimen shape
- Dose
- figure withheld
- Scale
- Microgram to low milligram-scale
- Route
- Subcutaneous injection, sometimes near the site
- Frequency
- Daily
- Timing
- No consistent relationship to food or training
- Duration
- Multi-week blocks, often repeated
Our read
The animal literature is real and reasonably consistent. The leap is treating rodent tendon healing as transferable — human tendon heals on a different timescale with different vascular supply, and there is no adequate published human trial. Local injection near a site does not obviously help either, since the proposed mechanisms are signalling rather than structural. The most likely explanation for reported improvement remains the natural healing curve plus whatever rehabilitation is happening alongside.
What the community reports
The comparison is between how sure the community is and how much is actually known — evidence strength, not direction. A compound can have solid research that came out negative.
The strongest belief-to-evidence mismatch on the platform. Treated as established fact across large parts of the fitness world, with scepticism often met with personal anecdote rather than argument, on an evidence base that is entirely animal.
Commonly reported as helping
- Faster resolution of tendon and joint pain, reported very widely
- Return to training sooner than expected
- Reduced pain during rehabilitation
- Reports of improvement in long-standing injuries that had not responded to anything else
Also reported, when it goes wrong
- A substantial minority report no effect at all
- Injection-site irritation
- Uncertainty about product identity, acknowledged even by advocates
- Reports of pain returning once use stops
Why these reports can mislead
Injuries improve on their own. That single fact accounts for most of what is reported here, and the timescale makes it worse — people typically start this after weeks of frustration, which is exactly when natural recovery is most likely to become noticeable anyway. Nobody posts about the injury that resolved without it.
Direct quotations are not published here yet. We will only carry verbatim reports once they are sourced, dated and checked — an unattributed quote is a testimonial, and testimonials are exactly what this section exists to replace.
Watch for, in this use specifically
- Do not let it displace loading rehabilitation.
- Earlier pain relief can lead to loading a tendon before it is structurally ready.
- Start one compound at a time or a reaction tells you nothing about its cause.
Gut symptoms, taken orally
What is run
Oral capsules or solution, daily, often for reflux or inflammatory bowel symptoms — sometimes alongside the injected form.
Their mechanistic reasoning
That the original research was gastrointestinal and the sequence derives from a protein found in gastric juice, so oral delivery to the gut is the most native route and avoids the systemic absorption question entirely.
Reported in the community’s own terms. Not our position.
Stacked with
- The injected form—Run together on the reasoning that local and systemic effects differ.
Regimen shape
- Dose
- figure withheld
- Scale
- Microgram to low milligram-scale
- Route
- Oral, capsule or solution
- Frequency
- Daily, sometimes divided
- Timing
- Often before food
- Duration
- Multi-week blocks
Our read
This is mechanistically better reasoned than the injectable use, and it deserves saying. The animal work genuinely was gastrointestinal, local action on gut mucosa sidesteps the absorption problem that undermines systemic claims, and the route matches the original research context. It is still untested in humans and 'more coherent than the alternative' is a low bar. But of the ways this compound gets used, this is the one whose logic holds up best.
What the community reports
The comparison is between how sure the community is and how much is actually known — evidence strength, not direction. A compound can have solid research that came out negative.
Believed in strongly by people with reflux or inflammatory bowel symptoms, and the reasoning offered is better than for the injected use — which the more informed part of the community recognises.
Commonly reported as helping
- Reduced reflux symptoms
- Improved tolerance of foods that previously caused problems
- Reduced gut discomfort during flares
Also reported, when it goes wrong
- No effect in a significant proportion
- Symptoms returning after stopping
- Uncertainty about whether oral material survives to act at all
Why these reports can mislead
Gastrointestinal symptoms fluctuate substantially on their own and respond strongly to expectation — placebo response rates in functional gut disorder trials are among the highest in medicine. People also change their diet when they start something for their gut, which is a real intervention running alongside.
Direct quotations are not published here yet. We will only carry verbatim reports once they are sourced, dated and checked — an unattributed quote is a testimonial, and testimonials are exactly what this section exists to replace.
Watch for, in this use specifically
- Persistent gut symptoms deserve a diagnosis. Masking reflux or inflammatory symptoms delays finding out what is actually wrong, and that delay can matter.
- No adequate human safety data for either route.
Active clinical trials
No registered trials currently tracked for BPC-157.
What remains unknown
The questions that would change our assessment if they were answered.
- Does any effect observed in rodents occur in humans at all?
- What happens to a systemically administered peptide of this size in humans — absorption, stability, distribution?
- Would an effect on tissue growth signalling carry oncological risk over time?
References
- 1.Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019.PMID 30915550doi
- 2.Sikiric P, Seiwerth S, Grabarevic Z, et al. Beneficial effect of a novel pentadecapeptide BPC 157 on gastric lesions induced by restraint stress, ethanol, indomethacin, and capsaicin neurotoxicity. Dig Dis Sci. 1996;41(8):1604-14.PMID 8769287doi
Editorial change history
When we change a grade or a regulatory note, we log it here rather than editing quietly.
Regulatory note clarified to distinguish compounding-committee consideration from approval, after reader confusion.
Downgraded from preliminary to preclinical after re-reading the cited human literature.
Spotted something wrong? Tell us — we publish corrections.